Boston Scientific (BSX) 10-K2024 FY Annual report

Filed: 18 Feb 25, 4:13pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AMF, Bolt, Braun, Brown, budget, buildup, bundle, called, cannibalization, capped, carotid, Chairman, chemotherapy, Cheryl, CID, Clawback, colorectal, commensurate, Cortex, Cryterion, Emily, extraterritorial, FARAVIEW, FARAWAVE, floxuridine, grid, Habiger, HDx, healthier, hepatic, Hub, hybrid, infusion, Intera, lag, leg, lithotripsy, Mann, metastatic, NAV, noncurrent, OPAL, paused, Pioneer, port, predominant, Prime, pump, quantum, reciprocal, repayment, retaliatory, revascularization, Road, sensing, shipment, Silk, slowdown, spectrum, strait, tariff, TENACIO, threshold, transcarotid, Trump, TruSteer, vacuum, Vance, verified, Woodworth

Removed: Abbott, ABIMED, AMBIMO, America, Angiotech, banking, Battery, begun, behavior, Biotronik, bound, Brasil, Brazilian, BSB, BTG, buyer, CADE, carry, chose, Colombia, combat, commissioner, concluding, conditional, conserving, consigned, Cook, count, cut, deny, discrimination, donated, elimination, elite, EnduraLife, equality, Fenner, fined, Hemoclip, Hereunder, injunction, Instinct, Inter, IPR, Islander, Johnson, Jonathan, Jude, Korea, Korean, Latin, launching, LEED, LIBOR, lost, Ltda, Lynch, MA, magnetic, Math, Merrill, milestone, mindful, Mitsui, modifying, Monson, Montage, MoXy, Native, neutrality, Nikko, NRG, obsolescence, Pacific, pandemic, person, Pierce, possession, posted, precision, preponderance, Preventice, Printed, prolonged, publication, racial, recommend, recommendation, recommended, remitted, remitting, reorganization, representation, request, resonance, Rhythmia, rollforward, seller, sensitivity, settled, shortening, SMBC, Smith, solar, South, specialty, St, Steering, Subtopic, suit, suite, Sumitomo, superseding, sustain, territorial, thereunder, Transseptal, UFJ, USPTO, Vertiflex, Victory, women, won, worsen, writing, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated BSX transcripts

BSX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.

SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:


			(1)			the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
			(2)			the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.



By:			/s/ Daniel J. Brennan
			Daniel J. Brennan
			Executive Vice President and Chief Financial Officer

			February 18, 2025